Conditioned Pharmacotherapeutic Effects in Hypertension

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of Rochester
Sponsor:
Information provided by (Responsible Party):
John Bisognano, University of Rochester
ClinicalTrials.gov Identifier:
NCT02056626
First received: February 4, 2014
Last updated: February 5, 2014
Last verified: February 2014
  Purpose

The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy. It will be determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be effectively treated with smaller cumulative amounts of drug.


Condition Intervention Phase
Hypertension
Drug: carvedilol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Conditioned Pharmacotherapeutic Effects in Hypertension

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • systolic blood pressure [ Time Frame: up to 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 121
Study Start Date: March 2011
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: arm 2
partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
Drug: carvedilol
Active Comparator: arm 3
controlled dosing schedule 6.25 mg twice daily (15 days)
Drug: carvedilol
Active Comparator: arm 4
controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
Drug: carvedilol
Active Comparator: arm 1
standard therapy, 25 mg twice daily (15 days)
Drug: carvedilol

Detailed Description:

The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy. In a double-blind, randomized, parallel-controlled clinical trial, It will be determined if, capitalizing on conditioned pharmacotherapeutic effects, patients can be effectively treated with smaller cumulative amounts of drug. To this end, some hypertensive patients will be treated on a partial rather than a continuous schedule of pharmacologic reinforcement. These patients will be compared to: (a) patients who continue to be treated under a standard regimen of pharmacotherapy at an effective dose of drug, and (b) patients who receive the same (reduced) cumulative amount of medication on a continuous schedule of reinforcement as that received by experimental patients treated under a partial schedule of reinforcement, and (c) patients who receive the same dose and frequency of carvedilol as the Partial Reinforcement Group but receive no intervening conditioned stimuli.

It is possible that a non-continuous schedule of pharmacologic reinforcement (and the concomitant reduced amount of active drug) will exert effects that are indistinguishable from a continuous (standard) regimen of pharmacotherapy (a higher cumulative amount of drug). That outcome or comparison, however, is not critical for evaluating the role of conditioning in the pharmacotherapy of hypertension. Specifically, we will test the hypotheses that:

  1. patients treated under a partial schedule of antihypertensive medication will show a greater amelioration of symptoms than that achieved by patients treated with that same (reduced) amount of drug administered under a continuous schedule of reinforcement;

    Conditions permitting, we will also test the predictions that:

  2. irrespective of initial treatment regimen, relapse will occur more quickly following withdrawal of active medication in patients who do not continue to receive conditioned stimuli (placebo) than in patients who continue to receive conditioned stimuli; and
  3. when active drug is withdrawn and replaced by conditioned stimuli alone, resistance to extinction will be greater (i.e., rate of relapse will be less) among patients treated under a partial schedule of reinforcement than patients treated with the same amount of drug administered under a continuous schedule of reinforcement (the partial reinforcement effect).

Positive results would transform the study and practice of pharmacotherapy with respect to placebo effects by providing a new model within which to design treatment protocols for patients with chronic diseases that capitalizes on conditioned pharmacotherapeutic responses. The model, from which testable hypotheses can be derived, also provides a new framework for research on placebo effects and the mechanisms underlying such phenomena.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • systolic blood pressure between 140-160 mmHG
  • between 18-80 years old

Exclusion Criteria:

  • abnormal renal function
  • currently pregnant, or trying to become pregnant
  • being treated with a beta-blocker
  • use of illicit drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02056626

Contacts
Contact: John D Bisognano, M.D., Ph.D 585-341-7700

Locations
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Robin Stuart Buttles, MSACN, CCRC    585-341-7700      
Principal Investigator: John D Bisognano, M.D., Ph.D         
Sub-Investigator: Francisco Tausk, M.D.         
Sub-Investigator: Jan Moynihan, M.D.         
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: John D. Bisognano, M.D., Ph.D. University of Rochester
  More Information

Publications:
Responsible Party: John Bisognano, M.D., Ph.D, University of Rochester
ClinicalTrials.gov Identifier: NCT02056626     History of Changes
Other Study ID Numbers: 5R01HL105520
Study First Received: February 4, 2014
Last Updated: February 5, 2014
Health Authority: United States: Institutional Review Board
United States: National Institutes for Health

Keywords provided by University of Rochester:
hypertension

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 02, 2014